Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AFSHIN GABAYAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1659412757
CMS profile
75537
Location
BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,187.22

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,151.33 234
Education $35.89 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AFSHIN GABAYAN

NPI 1659412757 · CMS profile ID 75537

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AFSHIN GABAYAN, NPI 1659412757, CMS profile ID 75537, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1659412757?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $3,187.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.1905/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673796113 CMS
PFIZER INC. $3.4905/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673798527 CMS
PFIZER INC. $1.4805/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673813961 CMS
Novartis Pharmaceuticals Corporation $17.2205/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548225 CMS
Celgene Corporation $29.9905/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672798117 CMS
E.R. Squibb & Sons, L.L.C. $12.5505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275789 CMS
E.R. Squibb & Sons, L.L.C. $2.4505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275791 CMS
EISAI INC. $14.3704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697006999 CMS
Puma Biotechnology, Inc. $22.9804/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706019481 CMS
Pharmacyclics LLC, An AbbVie Company $20.7504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665702797 CMS
AstraZeneca Pharmaceuticals LP $24.3404/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685338423 CMS
Janssen Biotech, Inc. $17.1904/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658435457 CMS
E.R. Squibb & Sons, L.L.C. $2.7304/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275779 CMS
E.R. Squibb & Sons, L.L.C. $15.5104/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275781 CMS
Genentech USA, Inc. $21.9804/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681195139 CMS
Genentech USA, Inc. $0.1404/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681248487 CMS
Genentech USA, Inc. $2.2104/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681315887 CMS
Novartis Pharmaceuticals Corporation $13.9204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548223 CMS
Incyte Corporation $15.3804/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666260253 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.1304/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697386981 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.9404/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697386989 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.4604/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697412109 CMS
Janssen Biotech, Inc. $23.5103/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658435451 CMS
Amgen Inc. $23.0703/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662150373 CMS
Merck Sharp & Dohme Corporation $19.8803/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695389929 CMS
E.R. Squibb & Sons, L.L.C. $2.3003/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275767 CMS
E.R. Squibb & Sons, L.L.C. $7.6103/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275769 CMS
E.R. Squibb & Sons, L.L.C. $0.2103/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275777 CMS
Novartis Pharmaceuticals Corporation $12.8603/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548221 CMS
Teva Pharmaceuticals USA, Inc. $16.9303/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697776433 CMS
Novartis Pharmaceuticals Corporation $17.9503/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548203 CMS
AstraZeneca Pharmaceuticals LP $18.3503/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685391173 CMS
E.R. Squibb & Sons, L.L.C. $2.8203/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275759 CMS
E.R. Squibb & Sons, L.L.C. $10.7803/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275765 CMS
E.R. Squibb & Sons, L.L.C. $0.2303/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651275775 CMS
PFIZER INC. $13.3003/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673798067 CMS
EISAI INC. $21.5203/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697001265 CMS
PFIZER INC. $14.8903/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673801847 CMS
PFIZER INC. $11.0503/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673802541 CMS
PFIZER INC. $2.3303/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673816581 CMS
Incyte Corporation $18.9003/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666260183 CMS
PFIZER INC. $14.5502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673798169 CMS
PFIZER INC. $2.1502/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673821733 CMS
Janssen Biotech, Inc. $18.0402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658435443 CMS
PFIZER INC. $12.3402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673799149 CMS
PFIZER INC. $1.7102/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673801835 CMS
PFIZER INC. $1.5402/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673816593 CMS
Genentech USA, Inc. $22.2802/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295253 CMS
Seattle Genetics, Inc. $22.8802/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678804245 CMS
Amgen Inc. $30.7002/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662150377 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,187.22 237
PY2020 $2,807.09 63
PY2021 $11,987.54 113
PY2022 $8,498.00 125
PY2023 $6,143.78 109
PY2024 $6,440.54 87
PY2025 $6,422.17 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,046.17 4
PY2025 Principal investigator $3,611,094.02 289
PY2024 Recipient $1,880.00 2
PY2024 Principal investigator $2,546,132.13 153
PY2023 Recipient $4,800.00 4
PY2023 Principal investigator $2,392,774.59 194
PY2022 Principal investigator $3,229,541.26 109
PY2021 Recipient $1,270.00 2
PY2021 Principal investigator $974,553.33 64
PY2020 Principal investigator $529,226.71 49
PY2019 Principal investigator $437,466.07 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

293 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $96.00 12/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202534245
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 12/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773067
Principal investigator 1 PFIZER INC. $12,452.07 12/31/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228815812
Principal investigator 1 PFIZER INC. $10,980.90 12/31/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228816353
Principal investigator 1 Coherus Oncology, Inc. $2,041.00 12/23/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252290
Principal investigator 1 Coherus Oncology, Inc. $1,899.00 12/23/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252295
Principal investigator 1 Coherus Oncology, Inc. $2,041.00 12/23/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252387
Principal investigator 1 Coherus Oncology, Inc. $2,041.00 12/23/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252390
Principal investigator 1 PFIZER INC. $23,971.08 12/23/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717427
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912211
Principal investigator 1 Aveo Pharmaceuticals, Inc. $5,740.00 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912239
Principal investigator 1 Aveo Pharmaceuticals, Inc. $5,740.00 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912331
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $33,000.00 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
ALI-1201 No dispute reported 06/30/2026 1251753320
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912261
Principal investigator 1 Aveo Pharmaceuticals, Inc. $186.20 12/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912285
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $58.30 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998593
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $19.98 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998595
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $73.00 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998597
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1.83 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998599
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20.50 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998601
Principal investigator 1 PFIZER INC. $2,000.00 12/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715737
Principal investigator 1 PFIZER INC. $3,683.93 12/17/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228816077
Principal investigator 1 PFIZER INC. $12,881.70 12/17/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228816566
Principal investigator 1 PFIZER INC. $11,861.60 12/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228816836
Principal investigator 1 Aveo Pharmaceuticals, Inc. $75.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912197
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912199
Principal investigator 1 Aveo Pharmaceuticals, Inc. $162.40 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912205
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912209
Principal investigator 1 Aveo Pharmaceuticals, Inc. $166.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912219
Principal investigator 1 Aveo Pharmaceuticals, Inc. $65.80 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912225
Principal investigator 1 Aveo Pharmaceuticals, Inc. $273.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912231
Principal investigator 1 Aveo Pharmaceuticals, Inc. $81.20 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912233
Principal investigator 1 Aveo Pharmaceuticals, Inc. $299.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912235
Principal investigator 1 Aveo Pharmaceuticals, Inc. $71.40 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912247
Principal investigator 1 Aveo Pharmaceuticals, Inc. $42.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912251
Principal investigator 1 Aveo Pharmaceuticals, Inc. $145.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912255
Principal investigator 1 Aveo Pharmaceuticals, Inc. $85.40 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912259
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912291
Principal investigator 1 Aveo Pharmaceuticals, Inc. $166.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912293
Principal investigator 1 Aveo Pharmaceuticals, Inc. $315.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912297
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912299
Principal investigator 1 Aveo Pharmaceuticals, Inc. $186.20 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912309
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912313
Principal investigator 1 Aveo Pharmaceuticals, Inc. $299.60 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912315
Principal investigator 1 Aveo Pharmaceuticals, Inc. $420.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912317
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912321
Principal investigator 1 PFIZER INC. $465.75 12/11/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228816422
Principal investigator 1 PFIZER INC. $13,258.35 12/09/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228815515
Recipient ABBVIE INC. $80.21 12/05/2025 Covered Recipient Physician Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO) No dispute reported 06/30/2026 1202398214
Recipient ABBVIE INC. $15.96 12/05/2025 Covered Recipient Physician Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202398218
Principal investigator 1 ABBVIE INC. $7,350.00 12/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202529304
Principal investigator 1 PFIZER INC. $12,136.72 12/03/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715827
Principal investigator 1 PFIZER INC. $9,060.00 12/03/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228815876
Principal investigator 1 Aveo Pharmaceuticals, Inc. $119.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912201
Principal investigator 1 Aveo Pharmaceuticals, Inc. $210.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912203
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912207
Principal investigator 1 Aveo Pharmaceuticals, Inc. $210.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912213
Principal investigator 1 Aveo Pharmaceuticals, Inc. $300.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912215
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912217
Principal investigator 1 Aveo Pharmaceuticals, Inc. $182.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912221
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912223
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912237
Principal investigator 1 Aveo Pharmaceuticals, Inc. $300.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912249
Principal investigator 1 Aveo Pharmaceuticals, Inc. $119.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912253
Principal investigator 1 Aveo Pharmaceuticals, Inc. $300.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912257
Principal investigator 1 Aveo Pharmaceuticals, Inc. $259.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912287
Principal investigator 1 Aveo Pharmaceuticals, Inc. $329.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912289
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912295
Principal investigator 1 Aveo Pharmaceuticals, Inc. $560.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912301
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912303
Principal investigator 1 Aveo Pharmaceuticals, Inc. $259.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912305
Principal investigator 1 Aveo Pharmaceuticals, Inc. $259.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912307
Principal investigator 1 Aveo Pharmaceuticals, Inc. $259.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912311
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912319
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912323
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912325
Principal investigator 1 Aveo Pharmaceuticals, Inc. $280.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912327
Principal investigator 1 Aveo Pharmaceuticals, Inc. $119.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912329
Principal investigator 1 PFIZER INC. $46,207.89 12/01/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228719163
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 11/30/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773065
Principal investigator 1 PFIZER INC. $16,146.00 11/27/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228712554
Principal investigator 1 PFIZER INC. $46,207.89 11/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717447
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,395.00 11/26/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814513
Principal investigator 1 PFIZER INC. $162.00 11/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228712556
Principal investigator 1 PFIZER INC. $1,068.45 11/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228818582
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $328.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814501
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,395.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814503
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,395.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814505
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,395.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814507
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $184.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814509
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $112.18 11/24/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814511
Principal investigator 1 PFIZER INC. $23,971.08 11/24/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717449
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7,672.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912151
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912153
Principal investigator 1 Aveo Pharmaceuticals, Inc. $140.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912155
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912157
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912159
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7,672.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912161
Principal investigator 1 Aveo Pharmaceuticals, Inc. $315.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912163
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,648.60 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912165
Principal investigator 1 Aveo Pharmaceuticals, Inc. $175.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912167
Principal investigator 1 Aveo Pharmaceuticals, Inc. $350.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912169
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912171
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,998.80 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912173
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912175
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912177
Principal investigator 1 Aveo Pharmaceuticals, Inc. $546.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912179
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912181
Principal investigator 1 Aveo Pharmaceuticals, Inc. $42.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912183
Principal investigator 1 Aveo Pharmaceuticals, Inc. $7,672.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912185
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912187
Principal investigator 1 Aveo Pharmaceuticals, Inc. $35.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912189
Principal investigator 1 Aveo Pharmaceuticals, Inc. $630.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912191
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912193
Principal investigator 1 Aveo Pharmaceuticals, Inc. $420.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912195
Principal investigator 1 Aveo Pharmaceuticals, Inc. $182.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912229
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,648.60 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912241
Principal investigator 1 Aveo Pharmaceuticals, Inc. $105.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912243
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912245
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,998.80 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912263
Principal investigator 1 Aveo Pharmaceuticals, Inc. $186.20 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912265
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912267
Principal investigator 1 Aveo Pharmaceuticals, Inc. $5,600.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912269
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,438.60 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912271
Principal investigator 1 Aveo Pharmaceuticals, Inc. $91.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912273
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,998.80 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912275
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,998.80 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912277
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912279
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,758.00 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912281
Principal investigator 1 Aveo Pharmaceuticals, Inc. $6,648.60 11/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912283
Principal investigator 1 PFIZER INC. $35,371.90 11/18/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228712286
Principal investigator 1 PFIZER INC. $48,832.20 11/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228715999
Principal investigator 1 PFIZER INC. $12,287.72 11/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228716001
Principal investigator 1 PFIZER INC. $3,330.01 11/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228818848
Principal investigator 1 Aveo Pharmaceuticals, Inc. $49.00 11/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912227
Recipient PFIZER INC. $620.00 11/10/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802909
Principal investigator 1 ABBVIE INC. $11,500.00 11/05/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202521667
Principal investigator 1 PFIZER INC. $12,136.72 11/05/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715903
Principal investigator 1 PFIZER INC. $50.69 11/04/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228818623
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 10/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773061
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,246.94 10/30/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814497
Principal investigator 1 PFIZER INC. $23,971.08 10/28/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717407
Principal investigator 1 PFIZER INC. $82,611.90 10/28/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228825745
Principal investigator 1 PFIZER INC. $3,957.93 10/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228826078
Principal investigator 1 PFIZER INC. $1,008.45 10/21/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228825521
Principal investigator 1 PFIZER INC. $45,512.70 10/20/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715739
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,950.68 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS, LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185552551
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $92.00 10/15/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814491
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $487.00 10/15/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814493
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $92.00 10/15/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814495
Principal investigator 1 PFIZER INC. $59,023.90 10/15/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228825664
Principal investigator 1 ABBVIE INC. $5,750.00 10/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202513715
Principal investigator 1 PFIZER INC. $2,744.75 10/09/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228825048
Principal investigator 1 PFIZER INC. $7,411.48 10/09/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228825342
Principal investigator 1 PFIZER INC. $12,136.72 10/08/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715825
Principal investigator 1 PFIZER INC. $35,371.90 10/08/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center Optima Diagnostic Imaging
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228717405
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $466.91 10/07/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814499
Principal investigator 1 PFIZER INC. $23,971.08 10/03/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717425
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 09/30/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773059
Principal investigator 1 PFIZER INC. $56,386.80 09/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228836487
Principal investigator 1 ABBVIE INC. $21,840.00 09/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202512390
Principal investigator 1 PFIZER INC. $12,501.20 09/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228835695
Principal investigator 1 PFIZER INC. $465.75 09/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228836434
Principal investigator 1 PFIZER INC. $500.00 09/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836497
Principal investigator 1 PFIZER INC. $6,555.69 09/19/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228835672
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,287.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912137
Principal investigator 1 Aveo Pharmaceuticals, Inc. $8,800.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912139
Principal investigator 1 Aveo Pharmaceuticals, Inc. $5,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912141
Principal investigator 1 Aveo Pharmaceuticals, Inc. $60,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912143
Principal investigator 1 Aveo Pharmaceuticals, Inc. $9,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912145
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,250.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912147
Principal investigator 1 Aveo Pharmaceuticals, Inc. $10,000.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199912149
Principal investigator 1 Coherus Oncology, Inc. $1,899.00 09/16/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252299
Principal investigator 1 Coherus Oncology, Inc. $1,208.00 09/16/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252303
Principal investigator 1 PFIZER INC. $15,635.70 09/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228835638
Principal investigator 1 PFIZER INC. $46,207.89 09/15/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228719090
Principal investigator 1 PFIZER INC. $46,207.89 09/14/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717471
Principal investigator 1 PFIZER INC. $12,136.72 09/10/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715657
Principal investigator 1 PFIZER INC. $21,223.14 09/08/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center Optima Diagnostic Imaging
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228717409
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,590.00 09/04/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $442.28 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814479
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,895.69 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814481
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,212.92 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814483
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $459.24 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814485
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,750.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814487
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $395.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814489
Principal investigator 1 PFIZER INC. $23,971.08 09/03/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717445
Principal investigator 1 PFIZER INC. $5,436.85 09/03/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228836426
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 08/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773063
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $53.67 08/26/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998583
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $151.58 08/26/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998585
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.00 08/26/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998587
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.66 08/26/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998589
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $46.00 08/26/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998591
Principal investigator 1 PFIZER INC. $2,560.95 08/23/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228842831
Principal investigator 1 PFIZER INC. $3,957.93 08/23/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842837
Principal investigator 1 PFIZER INC. $162.00 08/22/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228843729
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/20/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA No dispute reported 06/30/2026 1192185962
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 08/20/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA No dispute reported 06/30/2026 1192185965
Principal investigator 1 PFIZER INC. $9,262.01 08/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228843405
Principal investigator 1 PFIZER INC. $81,041.05 08/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228843668
Principal investigator 1 PFIZER INC. $2,217.44 08/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228843738
Principal investigator 1 PFIZER INC. $12,136.72 08/13/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228716003
Principal investigator 1 PFIZER INC. $23,971.08 08/07/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228717469
Recipient PFIZER INC. $330.00 08/05/2025 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228802915
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,421.00 08/02/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,421.00 08/02/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814471
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $426.00 08/02/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814473
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,421.00 08/02/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814475
Principal investigator 1 PFIZER INC. $10,999.39 08/02/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228843746
Principal investigator 1 Coherus Oncology, Inc. $6,957.00 07/31/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252286
Principal investigator 1 PFIZER INC. $3,478.43 07/25/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228847404
Principal investigator 1 PFIZER INC. $1,768.20 07/25/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228847420
Principal investigator 1 PFIZER INC. $5,824.15 07/25/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228847493
Principal investigator 1 Coherus Oncology, Inc. $994.81 07/23/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252307
Principal investigator 1 PFIZER INC. $18,205.08 07/16/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715655
Principal investigator 1 PFIZER INC. $38,403.45 07/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228847501
Principal investigator 1 PFIZER INC. $32,277.25 07/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228847555
Principal investigator 1 PFIZER INC. $36,450.00 07/11/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228847337
Principal investigator 1 PFIZER INC. $631.56 07/11/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228847484
Principal investigator 1 PFIZER INC. $21,239.26 07/07/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228716077
Principal investigator 1 PFIZER INC. $2,700.96 07/01/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228847414
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 06/30/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773057
Principal investigator 1 PFIZER INC. $40,748.42 06/27/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228851492
Principal investigator 1 PFIZER INC. $25,490.70 06/27/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228851507
Principal investigator 1 PFIZER INC. $17,599.90 06/27/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228852155
Principal investigator 1 Coherus Oncology, Inc. $110,250.00 06/26/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
CHS38802 No dispute reported 06/30/2026 1235252280
Principal investigator 1 PFIZER INC. $627.75 06/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228852167
Principal investigator 1 PFIZER INC. $15,047.54 06/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228852217
Principal investigator 1 AstraZeneca Pharmaceuticals LP $143,263.23 06/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS, LLC
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer No dispute reported 06/30/2026 1185552555
Principal investigator 1 PFIZER INC. $46,207.89 06/23/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228822520
Principal investigator 1 PFIZER INC. $46,207.89 06/22/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228833878
Principal investigator 1 AstraZeneca Pharmaceuticals LP $115,700.00 06/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS, LLC
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185552557
Principal investigator 1 PFIZER INC. $35,371.90 06/17/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842134
Principal investigator 1 PFIZER INC. $30,341.80 06/16/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842166
Principal investigator 1 PFIZER INC. $15,645.60 06/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228852225
Principal investigator 1 AstraZeneca Pharmaceuticals LP $240,351.58 06/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS, LLC
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 No dispute reported 06/30/2026 1185552553
Principal investigator 1 PFIZER INC. $2,560.95 06/07/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228851501
Principal investigator 1 PFIZER INC. $12,136.72 06/04/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842149
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 05/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773055
Principal investigator 1 PFIZER INC. $2,780.25 05/28/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228858281
Principal investigator 1 PFIZER INC. $14,996.85 05/23/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858196
Principal investigator 1 PFIZER INC. $1,831.95 05/23/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228858202
Principal investigator 1 PFIZER INC. $2,832.30 05/23/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228858274
Principal investigator 1 PFIZER INC. $12,136.72 05/21/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842172
Principal investigator 1 PFIZER INC. $8,398.35 05/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228858213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $113,250.00 05/01/2025 Non-covered Recipient Entity
Clinical Research Advisors LLC
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220814467
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 04/30/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773053
Principal investigator 1 PFIZER INC. $5,858.45 04/29/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228859914
Principal investigator 1 PFIZER INC. $4,365.90 04/29/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228859962
Principal investigator 1 PFIZER INC. $467.10 04/25/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228860556
Principal investigator 1 PFIZER INC. $5,863.14 04/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858148
Principal investigator 1 PFIZER INC. $2,000.00 04/23/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228842144
Principal investigator 1 PFIZER INC. $324.00 04/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228859569
Principal investigator 1 PFIZER INC. $10,064.25 04/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228859577
Principal investigator 1 PFIZER INC. $11,942.26 04/16/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228859905
Principal investigator 1 PFIZER INC. $15,871.19 04/08/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228858138
Principal investigator 1 PFIZER INC. $1,008.45 04/08/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228859582
Principal investigator 1 PFIZER INC. $4,296.55 04/01/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228859600
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 03/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773051
Principal investigator 1 PFIZER INC. $46,207.89 03/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228822526
Principal investigator 1 PFIZER INC. $46,207.89 03/30/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228833885
Principal investigator 1 PFIZER INC. $12,536.10 03/28/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228862153
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA No dispute reported 06/30/2026 1192185951
Principal investigator 1 GlaxoSmithKline, LLC. $12,250.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
A PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BELANTA No dispute reported 06/30/2026 1192185957
Principal investigator 1 PFIZER INC. $54,521.62 03/22/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228862168
Principal investigator 1 PFIZER INC. $6,704.20 03/22/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228863042
Principal investigator 1 PFIZER INC. $2,560.95 03/22/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228863048
Principal investigator 1 PFIZER INC. $30,273.75 03/14/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228862177
Principal investigator 1 PFIZER INC. $110,805.01 03/04/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863059
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 02/28/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773049
Principal investigator 1 PFIZER INC. $2,713.50 02/27/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228836422
Principal investigator 1 PFIZER INC. $48,406.15 02/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228836492
Principal investigator 1 PFIZER INC. $17,700.71 02/22/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228835631
Principal investigator 1 ABBVIE INC. $3,500.00 02/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ADVISORS LLC
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202452894
Principal investigator 1 PFIZER INC. $28,297.52 02/03/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center Optima Diagnostic Imaging
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228834648
Principal investigator 1 Boehringer Ingelheim International GmbH $133.41 01/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220773047
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 01/30/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
Phase Ib/expansion BI836880 in combination with CPI No dispute reported 06/30/2026 1220792041
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $35.78 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998569
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $151.58 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998571
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998573
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $219.00 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998575
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5.60 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998577
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12.20 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998579
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $59.00 01/27/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC) No dispute reported 06/30/2026 1220998581
Principal investigator 1 PFIZER INC. $1,279.80 01/25/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228862592
Principal investigator 1 PFIZER INC. $50,961.00 01/24/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
FIRSTINHUMAN FIH OPENLABEL PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY TOLERABILITY PK PD AND PRELIMINARY CLINICAL ACTIVITY OF PF07826390 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228863510
Principal investigator 1 PFIZER INC. $117,105.75 01/15/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1228863516
Principal investigator 1 PFIZER INC. $2,713.50 01/15/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
A PHASE 1B2 OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB PF06863135 A BCELL MATURATION ANTIGEN BCMA CD3 BISPECIFIC ANTIBODY IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA No dispute reported 06/30/2026 1228863526
Principal investigator 1 AstraZeneca UK Limited $163,446.40 01/13/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185552559
Principal investigator 1 Janssen Research & Development, LLC $334.00 01/13/2025 Non-covered Recipient Entity
Sarah Cannon Rsrch Inst Llc
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy No dispute reported 06/30/2026 1175273759
Principal investigator 1 PFIZER INC. $46,207.89 01/06/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228822532
Principal investigator 1 PFIZER INC. $46,207.89 01/05/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228834641